journal article·2026-01

Electric‐Field‐Mediated In Situ Electrocatalysis for Enhanced Chemodynamic Therapy and Immunotherapy via 3D Electrode Arrays

Lin‐Fang Tan, Xiao‐Lin Hou, Xiao‐Ting Xie, Meng Guan, Meng‐Wen Ma, Fang Zhang, Jin‐Xuan Fan, Bo Liu, Yuan‐Di Zhao, Qiu‐Ran Xu

Advanced Functional Materials· Volume 36· Issue 8
Publisher page

Abstract

Abstract Chemodynamic therapy (CDT) is widely applied in tumor treatment by inducing oxidative damage and immunogenic cell death (ICD). However, its therapeutic effects are constrained by the inherently low endogenous hydrogen peroxide levels and the suboptimal catalytic activity of metal ions. Herein, a tumor synergistic therapy platform based on a 3D electrode array is constructed to enhance local oxidative damage and activate systemic anti‐tumor immunity. By structurally optimizing the electric field distribution and increasing the electrode contact area, alternating current is used to drive electrode polarity switching, enabling dynamic coupling of the valence state conversion of oxygen species (H 2 O → O 2 → H 2 O 2 ) with the valence cycling of cerium ion (Ce 3+ /Ce 4+ ) on the electrode surface. This independent and continuous dynamic cascade electrocatalytic process amplified oxidative stress and disrupted the redox balance in tumor cells, triggering robust ICD. Meanwhile, electrical stimulation reprogrammed tumor‐associated macrophages (TAMs) from M2 to M1. Together, ICD‐induced immunogenicity and reprogrammed TAMs synergistically enhanced the anti‐tumor immune response. In vivo experiments demonstrated that the maturation rate of dendritic cells increased from 12.9% to 65.1%, M1 macrophages increased sevenfold, and tumor‐infiltrating cytotoxic T lymphocytes rose from 12.5% to 38.1%, resulting in the effective inhibition of hepatocellular carcinoma.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Molecular Communication and Nanonetworks

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Britton Chance Center for Biomedical Photonics at Wuhan National Laboratory for Optoelectronics – Hubei Bioinformatics & Molecular Imaging Key Laboratory Department of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan Hubei 430074 P. R. China

Key Laboratory of Biopharmaceutical Preparation and Delivery Chinese Academy of Sciences Beijing Beijing 100190 P. R. China

Key Laboratory of Biomedical Photonics (HUST) Ministry of Education Huazhong University of Science and Technology Wuhan Hubei 430074 P. R. China

Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine Zhejiang Provincial People's Hospital Affiliated People's Hospital Hangzhou Medical College Hangzhou Zhejiang 310014 P. R. China

Funding

National Natural Science Foundation of China

References (43)

Show source-provided references
1. 10.1002/adma.20210422310.1002/adma.202104223 ↗
2. 10.1021/acsnano.8b0763510.1021/acsnano.8b07635 ↗
3. 10.1002/ange.20180566410.1002/ange.201805664 ↗
4. 10.1021/acs.analchem.3c0062710.1021/acs.analchem.3c00627 ↗
5. 10.1002/adfm.20190612810.1002/adfm.201906128 ↗
6. 10.1016/j.jconrel.2023.03.02610.1016/j.jconrel.2023.03.026 ↗
7. 10.1002/anie.20171280310.1002/anie.201712803 ↗
8. 10.1016/j.jconrel.2023.06.01210.1016/j.jconrel.2023.06.012 ↗
9. 10.1021/acsnano.4c1001210.1021/acsnano.4c10012 ↗
10. 10.1021/acs.chemmater.9b0304210.1021/acs.chemmater.9b03042 ↗
11. 10.1002/smll.20207017410.1002/smll.202070174 ↗
12. 10.1002/advs.20240393510.1002/advs.202403935 ↗
13. 10.1016/j.nanoen.2016.04.00710.1016/j.nanoen.2016.04.007 ↗
14. 10.1021/acsbiomaterials.6b0036010.1021/acsbiomaterials.6b00360 ↗
15. 10.1002/anie.20221098010.1002/anie.202210980 ↗
16. 10.1038/s41467-023-42697-210.1038/s41467-023-42697-2 ↗
17. 10.1039/D1TA09915A10.1039/D1TA09915A ↗
18. 10.1039/D2TA09097J10.1039/D2TA09097J ↗
19. 10.1515/nanoph-2022-041710.1515/nanoph-2022-0417 ↗
20. 10.1016/j.mtadv.2022.10032910.1016/j.mtadv.2022.100329 ↗
21. 10.1002/adma.20220841410.1002/adma.202208414 ↗
22. 10.1016/j.bioelechem.2022.10826110.1016/j.bioelechem.2022.108261 ↗
23. 10.1002/advs.20230301610.1002/advs.202303016 ↗
24. 10.1016/j.mattod.2023.02.02610.1016/j.mattod.2023.02.026 ↗
25. 10.1007/s00262-020-02534-710.1007/s00262-020-02534-7 ↗
26. 10.1002/advs.20220716510.1002/advs.202207165 ↗
27. 10.1016/j.actbio.2023.04.02710.1016/j.actbio.2023.04.027 ↗
28. 10.1021/acsnano.4c0113210.1021/acsnano.4c01132 ↗
29. 10.1002/advs.20210096210.1002/advs.202100962 ↗
30. 10.1007/s10585-009-9262-y10.1007/s10585-009-9262-y ↗
31. 10.1016/j.lfs.2021.11925910.1016/j.lfs.2021.119259 ↗
32. 10.1016/j.nanoen.2022.10747110.1016/j.nanoen.2022.107471 ↗
33. 10.1016/j.cej.2022.14002610.1016/j.cej.2022.140026 ↗
34. 10.1007/s12274-019-2532-310.1007/s12274-019-2532-3 ↗
35. 10.1016/j.envres.2022.11344410.1016/j.envres.2022.113444 ↗
36. 10.1016/j.nanoen.2021.10620810.1016/j.nanoen.2021.106208 ↗
37. 10.1002/anie.20201602410.1002/anie.202016024 ↗
38. 10.1016/j.chempr.2023.12.00210.1016/j.chempr.2023.12.002 ↗
39. Yan X. · Chem. Soc. Rev. · 2018 · 47 · 20
40. 10.1158/0008-5472.CAN-06-098310.1158/0008-5472.CAN-06-0983 ↗
41. 10.1021/acsnano.3c0212610.1021/acsnano.3c02126 ↗
42. 10.1146/annurev-immunol-032712-09590610.1146/annurev-immunol-032712-095906 ↗
43. 10.3390/ijms2312685010.3390/ijms23126850 ↗